Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory
12 Setembro 2023 - 8:00AM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that the Company has received its Clinical Laboratory
Permit from the New York State Department of Health for its
laboratory in Pittsburgh.
“Castle is committed to serving patients through high-quality
molecular tests that inform important care decisions in the
management of conditions with high clinical need,” said Kristen
Oelschlager, chief operating officer of Castle Biosciences.
“Successful completion of the rigorous New York State licensure
process for our Pittsburgh laboratory reflects this commitment and
expands our ability to positively impact patient care.”
Castle operates clinical laboratories in Pittsburgh and Phoenix.
With the recent successful inspection in Pittsburgh, both
laboratories are now permitted to provide test services to patients
and physicians in the state of New York; Castle’s Phoenix
laboratory received its permit in early 2018. Both laboratories are
also College of American Pathologists (CAP) accredited and Clinical
Laboratory Improvement Amendments (CLIA) certified, reflecting
Castle’s commitment to high-quality standards and operational
excellence.
Earlier this year, Castle doubled the size of its Pittsburgh
operations through a move to a new state-of the art laboratory in
the city’s historic North Side. The 20,000 square-foot laboratory
provides additional capacity that should allow Castle to continue
to scale its operations and provide space for future growth. The
new laboratory in Pittsburgh brings Castle’s total laboratory
operations space to more than 52,000 square feet combined.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics
company improving health through innovative tests that guide
patient care. The Company aims to transform disease management by
keeping people first: patients, clinicians, employees and
investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the “safe harbor” created by those
sections. These forward-looking statements include, but are not
limited to, statements concerning: the potential of our additional
capacity to allow us to continue to scale our operations and
provide space for future growth. The words “can,” “should” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements that we make. These forward-looking
statements involve risks and uncertainties that could cause our
actual results to differ materially from those in the
forward-looking statements, including, without limitation: our
ability to maintain compliance with the CAP accreditation program’s
requirements on an ongoing basis; and the risks set forth under the
heading “Risk Factors” in our Annual Report on Form 10-K for the
year ended December 31, 2022 and in our other filings with the SEC.
The forward-looking statements are applicable only as of the date
on which they are made, and we do not assume any obligation to
update any forward-looking statements, except as may be required by
law.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912759416/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com Media Contact: Allison
Marshall amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024